The tweet was deleted by the author.
But we saved everything 🙂.
CVRx has announced that Humana will issue a Medicare Advantage coverage policy for Barostim therapy, with the policy set to become effective on May 1, 2026.
Humana is one of the largest national health insurance companies in the U.S., operating the second largest Medicare Advantage program and covering around 5.2 million individuals. The expansion of coverage for Barostim therapy marks a significant step for CVRx, broadening access to advanced heart failure treatment options for millions across the country. Details about the implementation and rollout of the new policy are expected as the effective date approaches.
CVRx recently began enrolling patients in the BENEFIT-HF trial at North Central Heart, one of the largest cardiac device studies to date. The company previously reported that its Barostim device improved quality of life for heart failure patients, citing a case shared by Dr. Savitri Fedson in a patient outcome report highlighting the therapy's impact. These developments come as CVRx continues to advance Barostim therapy in the heart failure treatment landscape.